ImpriMed is also working on solving the challenge of treating lymphoma in dogs, which is the most common cancer diagnosed in dogs. The company's AI-powered technology aims to increase the chances of successful treatment and potentially reduce unnecessary costs and side effects from less effective treatments. The company has already helped more than 5,000 dogs with lymphoma and has collected clinical outcome data from more than half of those patients. The recent funding will be used to expand its technology into human oncology, increase its workforce, and broaden its business development pipelines.
Key takeaways:
- ImpriMed, a California-based precision medicine startup, is expanding its AI-powered dog cancer treatment technology to human oncology applications. The technology helps identify the most suitable drugs for individual canine and feline blood cancers.
- The company recently raised $23 million in a Series A funding round, bringing its total raised to $35 million since its inception. The funds will be used to expand its drug response prediction technology beyond veterinary medicine into human oncology, increase its workforce and broaden its pipelines in business development.
- ImpriMed's veterinary services are fully commercialized, offering five canine and three feline services and generating revenue. More than 350 veterinarians in the U.S. have used its service.
- For human precision oncology, its AI software for multiple myeloma, a rare blood cancer, is in the process of approval, aiming to commercialize in 2025. It also offers a live-cell-based drug sensitivity test that lets pharmaceuticals measure the efficacy of new drug compounds on actual patients’ live cells of their target cancer.